Buy Or Sell Opportunity • Jun 03
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 40% to €34.24. The fair value is estimated to be €27.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 19% in a year. Earnings are forecast to grow by 56% in the next year. Tillkännagivande • May 01
Axogen, Inc., Annual General Meeting, Jun 23, 2026 Axogen, Inc., Annual General Meeting, Jun 23, 2026. Tillkännagivande • Apr 30
Axogen, Inc. Provides Earnings Guidance for the Full Year 2026 Axogen, Inc. provided earnings guidance for the full year 2026. For the period, The company expects 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%. Tillkännagivande • Apr 14
Axogen, Inc. to Report Q1, 2026 Results on Apr 28, 2026 Axogen, Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 28, 2026 Tillkännagivande • Feb 24
Axogen, Inc. Provides Earnings Guidance for the Year 2026 Axogen, Inc. provided earnings guidance for the year 2026. For the year,company expected revenue growth to be at least 18%, or $265.7 million, for the full-year and gross margin to be in the range of 74% to 76%. Tillkännagivande • Feb 10
Axogen, Inc. to Report Q4, 2025 Results on Feb 24, 2026 Axogen, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026 Tillkännagivande • Jan 13
Axogen, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2025 Axogen, Inc. provided preliminary unaudited earnings guidance for the fourth quarter and full year of 2025. For the quarter, the company expects revenue to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter of 2024, driven by solid performance across the product portfolio.
For the full year, the company expects revenue to be approximately $225.2 million, which represents a 20.2% increase over the full-year of 2024. Tillkännagivande • Dec 04
Axogen, Inc. Announces Fda Approval of Biologics License Application for Avance® Axogen, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has approved the Biologics License Application ("BLA") for AVANCE® (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities. The indications for sensory nerve discontinuities >25mm and for mixed and motor nerve discontinuities were approved under FDA's Accelerated Approval pathway based on the effect on static two-point discrimination in sensory nerve gaps 25mm, which provided empirical evidence to reasonably predict clinical benefit given similarities in pathophysiology and anticipated therapeutic effects. Continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies. The approved BLA and successful transition of Avance to a biologic regulatory framework should give all stakeholders the assurance that Avance has been rigorously evaluated and determined to be safe, pure, and potent for its intended use, and that its benefits outweigh its known or potential risks. Commercial availability of the licensed Avance product is expected early in the second quarter of 2026. In the timeframe, Avance remains available under the current tissue framework. Avance remains available under the currently tissue framework. Indications: AVANCE® is an a cellular nerve scaffold indicated for the treatment of adult and adult and pediatric patients aged one month and older with: Sensory nerve discontinuity (25mm); Sensory nerve discontinuity (>25mm); Approved under accelerated approval based on static two-point discrimination (s2PD) at 12 months in sensory nerve gaps 25 mm, which reasonably predicts clinical benefit. Continued approval is contingent upon confirmatory clinical trial results. Mixed and motor nerve discontinuity; Approved under accelerated approved based on s2PD outcomes in sensory nerve gaps 25 mm; continued approval is contingent upon confirmatoryclinical trial results. Mixed and motor spinal discontinuity; Approved under accelerate approval based on s2PD outcomes In addition, the company has approved the Biologics license Application for AVANCE® (ACllular nerve allograft-ARwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguards Nerve Protector™, Axoguard HA+ Nerve Protector™, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries. Tillkännagivande • Oct 29
Axogen, Inc. Raises Earnings Guidance for the Year 2025 Axogen, Inc. raised earnings guidance for the year 2025. For the year, company raised revenue guidance to at least 19% growth, or $222.8 million for the full year. Company continued to expect gross margin for the year to be in the range of 73% to 75%. Tillkännagivande • Oct 15
Axogen, Inc. to Report Q3, 2025 Results on Oct 29, 2025 Axogen, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 29, 2025 Tillkännagivande • Aug 25
Axogen, Inc. Provides Update on FDA Review Timeline for Avance Nerve Graft Axogen, Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance®? Nerve Graft by three months to December 5, 2025. On August 22, 2025, the Company received a communication from the FDA indicating that the information submitted by the Company in response to an FDA information request, which included substantial new manufacturing and facility data not previously reviewed by the Agency, was deemed a Major Amendment to its BLA. Under FDA guidelines, this designation allows for additional time to review the submission. As a result, the FDA has extended the PDUFA goal date to December 5, 2025. The FDA also informed the Company that it now anticipates providing feedback on product labeling in November 2025, consistent with PDUFA review procedures. Tillkännagivande • Aug 05
Axogen, Inc. Raises Earnings Guidance for the Year 2025 Axogen, Inc. raised earnings guidance for the year 2025 . For the year, company raising revenue guidance to at least 17% growth, or $219 million for the full year. We continue to expect gross margin for the year to be in the range of 73% to 75%. Tillkännagivande • Jul 23
Axogen, Inc. to Report Q2, 2025 Results on Aug 05, 2025 Axogen, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 05, 2025 Tillkännagivande • May 01
Axogen, Inc., Annual General Meeting, Jun 18, 2025 Axogen, Inc., Annual General Meeting, Jun 18, 2025. Tillkännagivande • Apr 24
Axogen, Inc. to Report Q1, 2025 Results on May 08, 2025 Axogen, Inc. announced that they will report Q1, 2025 results Pre-Market on May 08, 2025 Tillkännagivande • Feb 26
AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2025 AxoGen, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects revenue growth to be in the range of 15% to 17%. Tillkännagivande • Jan 11
Axogen, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024 Axogen, Inc. provided revenue guidance for the fourth quarter and full year 2024. For the quarter, the company's revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth quarter of 2023 driven by solid performance across the product portfolio.
Full-year 2024 revenue is expected to be approximately $187.3 million, which represents a 17.8% increase over the full-year of 2023. Tillkännagivande • Jan 10
Axogen, Inc. to Report Q4, 2024 Results on Mar 04, 2025 Axogen, Inc. announced that they will report Q4, 2024 results on Mar 04, 2025 New Risk • Nov 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Reported Earnings • Nov 09
Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.095 loss in 3Q 2023) Third quarter 2024 results: US$0.042 loss per share (improved from US$0.095 loss in 3Q 2023). Revenue: US$48.6m (up 18% from 3Q 2023). Net loss: US$1.86m (loss narrowed 55% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Nov 08
Axogen, Inc. Maintains Earnings Guidance for 2024 Axogen, Inc. maintained earnings guidance for 2024. For the period, the company expects revenue in the range of $182 million to $186 million. Breakeven Date Change • Nov 07
No longer forecast to breakeven The 6 analysts covering Axogen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.74m in 2025. New consensus forecast suggests the company will make a loss of US$4.30m in 2026. Tillkännagivande • Oct 24
Axogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Axogen, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 07, 2024 Breakeven Date Change • Oct 15
Forecast to breakeven in 2025 The 6 analysts covering Axogen expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$493.3k in 2025. Average annual earnings growth of 79% is required to achieve expected profit on schedule. New Risk • Aug 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$5.9m net loss in 2 years). Reported Earnings • Aug 09
Second quarter 2024 earnings released: US$0.044 loss per share (vs US$0.15 loss in 2Q 2023) Second quarter 2024 results: US$0.044 loss per share (improved from US$0.15 loss in 2Q 2023). Revenue: US$47.9m (up 26% from 2Q 2023). Net loss: US$1.92m (loss narrowed 71% from 2Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 08
AxoGen, Inc. Updates Earnings Guidance for the Full Year 2024 AxoGen, Inc. updated earnings guidance for the full year 2024. For the year, the company increased annual revenue guidance to the range of $182 million to $186 million. Tillkännagivande • Jul 23
AxoGen, Inc. to Report Q2, 2024 Results on Aug 08, 2024 AxoGen, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024 Breakeven Date Change • Jul 02
Forecast breakeven date pushed back to 2026 The 6 analysts covering AxoGen previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 49% per year to 2025. The company is expected to make a profit of US$17.7m in 2026. Average annual earnings growth of 84% is required to achieve expected profit on schedule. Tillkännagivande • Jun 24
Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix Axogen, Inc. announced the launch of its newest product, Avive+ Soft Tissue Matrix. Avive+ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product. Nerve protection represents approximately $800 million of the overall nerve repair market and covers a wide range of injuries and defects including carpal and cubital tunnel syndromes, crush injuries, and other non-transected traumatic nerve injuries. The diversity of these injury types and their anatomical locations present unique challenges and Axogen is committed to optimizing outcomes for patients, using its targeted portfolio of solutions to address the needs of each injury type, and the healing process. Avive+ Soft Tissue Matrix complements the Company’s existing portfolio of nerve protection products, which includes Axoguard Nerve Protector® and Axoguard HA+ Nerve Protector. Breakeven Date Change • Jun 16
Forecast breakeven date moved forward to 2025 The 5 analysts covering AxoGen previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 16% to 2024. The company is expected to make a profit of US$5.74m in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule. Breakeven Date Change • May 31
Forecast breakeven date moved forward to 2025 The 5 analysts covering AxoGen previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 16% to 2024. The company is expected to make a profit of US$5.74m in 2025. Average annual earnings growth of 97% is required to achieve expected profit on schedule. Tillkännagivande • May 03
Axogen, Inc. Provides Revenue Guidance for the Year 2024 AxoGen, Inc. provided revenue guidance for the year 2024. The company maintained its full year guidance with 2024 revenue in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%. Reported Earnings • May 02
First quarter 2024 earnings released: US$0.15 loss per share (vs US$0.17 loss in 1Q 2023) First quarter 2024 results: US$0.15 loss per share (improved from US$0.17 loss in 1Q 2023). Revenue: US$41.4m (up 13% from 1Q 2023). Net loss: US$6.64m (loss narrowed 6.2% from 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 30
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix Axogen, Inc. announced the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™?. Avive+ Soft Tissue matrix™? is a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of healing for nerves. Avive+ is processed and distributed as a 361 tissue product in accordance with U.S. Food and Drug Administration (FDA) Good Tissue Practice under 21 CFR part 1271 regulations. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, complex traumatic injuries, and surgical exposures. The diversity of these injury types and their anatomical locations present unique challenges for both the surgeon and the patient. To optimize recovery, Axogen provides solutions to adequately address the nerve and the surrounding environment throughout the healing process. Physical damage to a peripheral nerve, or the inability to properly connect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance®? Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging terminated peripheral nerve without the comorbidities associated with a second surgical site; Avive+ Soft TissueMatrix™?, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; Axoguard Nerve Connector®?, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerved Protector®?, a porcines submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™?, a porcine Submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®?, a porCine submucosa ECM products used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries. Tillkännagivande • Apr 26
AxoGen, Inc., Annual General Meeting, Jun 05, 2024 AxoGen, Inc., Annual General Meeting, Jun 05, 2024, at 08:00 US Eastern Standard Time. Agenda: To elect nine members to company board of directors to hold office for the ensuing year and until their successors are elected and qualified; to ratify the selection of Deloitte & Touche LLP as company independent registered public accounting firm for the year ending December 31, 2024; to approve the Axogen, Inc. third Amended and Restated 2019 long-term incentive plan to increase the number of shares authorized for issuance thereunder from 8,000,000 to 10,500,000; to consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof; and to consider other matters. Tillkännagivande • Apr 17
AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024 AxoGen, Inc. announced that they will report Q1, 2024 results Pre-Market on May 02, 2024 New Risk • Mar 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Significant insider selling over the past 3 months (€499k sold). Recent Insider Transactions • Mar 10
Vice President of Operations recently sold €293k worth of stock On the 7th of March, Michael Donovan sold around 36k shares on-market at roughly €8.06 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months. Tillkännagivande • Mar 10
AxoGen, Inc. Announces Executive Changes Angelo Scopelianos notified Axogen, Inc. of his intention to resign as the Company's Chief Research and Development Officer no later than March 31, 2024. Mr. Scopelianos will provide transition services as a consultant for a period commencing on the Separation Date and ending on December 31, 2024. The Consulting Period may be extended further upon mutual agreement of the Company and Mr. Scopelianos and may be terminated by the Company for cause. Mr. Scopelianos' product development responsibilities will be assumed by Ms. Stacy Arnold, Vice President of Product Development and Clinical Research, who is not an executive officer but is a member of the executive team and reports directly to the Company's CEO, Karen Zaderej. New Risk • Mar 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Significant insider selling over the past 3 months (€87k sold). Tillkännagivande • Mar 06
AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024 AxoGen, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenue to be in the range of $177 million to $181 million, which represents an annual growth rate of approximately 11% to 14%. Reported Earnings • Mar 05
Full year 2023 earnings released: US$0.51 loss per share (vs US$0.69 loss in FY 2022) Full year 2023 results: US$0.51 loss per share (improved from US$0.69 loss in FY 2022). Revenue: US$159.0m (up 15% from FY 2022). Net loss: US$21.7m (loss narrowed 25% from FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Breakeven Date Change • Mar 05
Forecast breakeven date pushed back to 2026 The 5 analysts covering AxoGen previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$25.3m in 2026. Average annual earnings growth of 55% is required to achieve expected profit on schedule. Tillkännagivande • Jan 19
Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study Axogen, Inc. announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05). Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group (p-value <0.05). Tillkännagivande • Dec 27
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors Axogen, Inc. announced the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board’s Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. Weiler is the Executive Vice President, Chief Commercial and Growth Officer at Amwell. Weiler oversees the company’s growth strategy, driving strategic initiatives and leading business development, sales and account management, commercial enablement, marketing, and strategic and channel partnership teams. Prior to Amwell, Weiler served as Chief Consumer Officer at Optum, where she led consumerism across the enterprise. Preceding that, she was Chief Consumer Strategy Officer at UnitedHealth Group and the Chief Marketing and Experience Officer of Optum Health, leading marketing efforts for Optum Care and Optum’s Population Health Solutions, Complex Care Management, Medical Benefits Management, Behavioral Health, Prevention and Financial Services businesses. Weiler also served as Chief Marketing and Product Officer at Blue Cross and Blue Shield of Massachusetts, where she drove strategic growth and retention business objectives. Weiler spent her earlier career with multiple financial services organizations. She was Chief Marketing Officer of Fidelity Investments FAS business and held senior marketing leadership roles at BNY Mellon/Pershing and The Hartford. Weiler holds a B.A. from Bowdoin College and an M.A. in International Economics and Finance from Brandeis University. Recent Insider Transactions • Dec 14
Insider recently sold €87k worth of stock On the 11th of December, Peter Mariani sold around 13k shares on-market at roughly €6.99 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €317k more than they bought in the last 12 months. Tillkännagivande • Dec 06
AxoGen, Inc. Announces CFO Changes Axogen, Inc. announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior finance executive with more than 20 years of experience primarily in the life sciences industry, he replaces Peter Mariani, who will depart Axogen following a brief transition period. The move aligns the executive team with the Company’s financial management and investor relations needs going forward as Axogen focuses on continued revenue growth across both business categories while driving toward being cash flow positive and profitable. Mr. Naor has diverse finance and operations leadership experience with public and private pharma, life sciences, and medtech companies worldwide. In previous roles, he managed global organizations with up to $2.5 billion in sales and built top-performing finance & accounting, IR, legal, contracting & pricing, IT, and big data analytics functions. Mr. Naor has served as the CFO of Arbor Pharmaceuticals and supported its strategic pivot. He was also the CFO U.S./Americas of Mölnlycke Healthcare, where he played a pivotal role in its growth and profitability improvement and was the founder of UCB’s global Portfolio Management and Resource Allocation function, as well as the company’s U.S. CFO. Earlier in his career, he held several finance leadership positions with AstraZeneca, served as a financial consultant and investment banker, worked as an auditor with KPMG, and practiced commercial law. He continues to advise and serve as a board member for emerging life sciences and technology companies. Mr. Naor holds a Master of Business Administration from IMD Business School in Switzerland, a master’s degree in law (LL.M.) from Hamburg University in Germany, and bachelor’s degrees in law (LL.B.) and in accounting from the Tel-Aviv University in Israel. Mr. Naor is also a CFA charter holder. Reported Earnings • Nov 09
Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.10 loss in 3Q 2022) Third quarter 2023 results: US$0.095 loss per share (improved from US$0.10 loss in 3Q 2022). Revenue: US$41.3m (up 12% from 3Q 2022). Net loss: US$4.09m (loss narrowed 5.3% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Tillkännagivande • Nov 08
Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023 AxoGen, Inc. provided revenue guidance for the full-year 2023. For the year, the company maintaining full-year 2023 revenue guidance in the range of $154 million to $159 million, which represents annual growth of 11% - 15%. Tillkännagivande • Oct 19
AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023 AxoGen, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023 Tillkännagivande • Sep 06
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector Axogen, Inc. announced the full launch of Axoguard HA+ Nerve Protector. Axoguard HA+ Nerve Protector is a proprietary nerve protection device uniquely designed to provide both short- and long-term protection for peripheral nerve injuries. The device is comprised of a processed porcine submucosa extracellular matrix base layer with a hyaluronate-alginate gel coating. The gel layer facilitates enhanced nerve gliding to aid in minimizing soft tissue attachments, while the base layer is remodeled into a long-term protective tissue layer. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, and complex traumatic injuries. The diversity of these injury types and their anatomical locations present unique challenges for both the surgeon and the patient. Optimizing outcomes requires targeted solutions to adequately address the nerve and the surrounding environment throughout the healing process. Recent Insider Transactions • Aug 20
Independent Director recently bought €56k worth of stock On the 16th of August, Guido Neels bought around 10k shares on-market at roughly €5.60 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €349k more in shares than they bought in the last 12 months. New Risk • Aug 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Significant insider selling over the past 3 months (€405k sold). Tillkännagivande • Aug 09
Axogen, Inc. Provides Revenue Guidance for the Year 2023 AxoGen, Inc. Provided revenue guidance for the year 2023. For the full year, the company provides revenue in the range of $154 million to $159 million which represents annual growth of 11% - 15%. Breakeven Date Change • Aug 08
Forecast to breakeven in 2025 The 5 analysts covering AxoGen expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 22% per year to 2024. The company is expected to make a profit of US$15.0m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule. Recent Insider Transactions • Jun 07
Director recently sold €341k worth of stock On the 1st of June, Gregory Freitag sold around 42k shares on-market at roughly €8.12 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €405k more than they bought in the last 12 months. Recent Insider Transactions • May 25
Director recently sold €64k worth of stock On the 23rd of May, Gregory Freitag sold around 7k shares on-market at roughly €8.56 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Tillkännagivande • May 10
AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023 AxoGen, Inc. provided earnings guidance for the full-year 2023. For the year, the company expects revenue to be in the range of $154 million to $159 million. Reported Earnings • May 10
First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.27 loss in 1Q 2022) First quarter 2023 results: US$0.17 loss per share (improved from US$0.27 loss in 1Q 2022). Revenue: US$36.7m (up 18% from 1Q 2022). Net loss: US$7.07m (loss narrowed 38% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year. Breakeven Date Change • Mar 28
No longer forecast to breakeven The 5 analysts covering AxoGen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$13.6m in 2025. New consensus forecast suggests the company will make a loss of US$1.93m in 2025. Breakeven Date Change • Mar 16
No longer forecast to breakeven The 5 analysts covering AxoGen no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$13.6m in 2025. New consensus forecast suggests the company will make a loss of US$1.47m in 2025. Reported Earnings • Mar 15
Full year 2022 earnings released: US$0.69 loss per share (vs US$0.66 loss in FY 2021) Full year 2022 results: US$0.69 loss per share (further deteriorated from US$0.66 loss in FY 2021). Revenue: US$138.6m (up 8.8% from FY 2021). Net loss: US$28.9m (loss widened 7.3% from FY 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 6% per year. Tillkännagivande • Feb 14
Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer Axogen, Inc. announced the appointment of Jens Schroeder Kemp to the newly created role of Chief Marketing Officer. Kemp brings more than 20 years of strategic marketing, sales, and business development experience in high-growing medical technology. As a member of the Axogen executive leadership team, Kemp will report directly to Karen Zaderej, Chairman, CEO and President, and will oversee the development and execution of the company’s marketing strategies. Mr. Kemp most recently served as Vice President of Marketing for Ambu Inc, where he led Ambu’s marketing efforts to create the single use endoscopy market across multiple clinical applications. Following Ambu’s acquisition of King Systems in 2012, Mr. Kemp developed and scaled the US marketing function with new capabilities in health economics and market access, market development and digital marketing. Across more than 15 years at Ambu, he had multiple roles in business development and marketing, and served as a member of the Global Management Team. Prior to Ambu, Mr. Kemp was a management consultant at PERA (Production and Engineering Research Association), where his role included sales, marketing, and innovation strategies for medical device and renewable energy products. Previously, he was co-founder of an artificial intelligence decision support software company Mindgroup ApS. Mr. Kemp has a bachelor’s degree in business administration, and a master’s degree in international marketing and management, both from Copenhagen Business School. Breakeven Date Change • Dec 31
Forecast to breakeven in 2025 The 5 analysts covering AxoGen expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$9.65m in 2025. Average annual earnings growth of 56% is required to achieve expected profit on schedule. Reported Earnings • Nov 09
Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.17 loss in 3Q 2021) Third quarter 2022 results: US$0.10 loss per share (improved from US$0.17 loss in 3Q 2021). Revenue: US$37.0m (up 18% from 3Q 2021). Net loss: US$4.32m (loss narrowed 40% from 3Q 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Tillkännagivande • Nov 09
AxoGen, Inc. Updates Earnings Guidance for the Full Year 2022 AxoGen, Inc. updated earnings guidance for the full year 2022. For the year, the company is narrowing the range of annual revenue guidance and expects revenue to be in the range of $137.5 million to $140.0 million versus the prior range of $135.0 million to $142.0 million. Full-year 2022 gross margin is expected to be above 80%. Tillkännagivande • Nov 01
Axogen, Inc. Announces Directorate Changes Axogen, Inc. announced that effective December 13, 2022, Adrian Tyndall, M.D., MPH, FACEP has been appointed as an independent member to the company's board of directors and will serve on the Quality, Compliance, and Portfolio Management Committee. The company also announced that Mark Gold, M.D. a founding director, will retire from the board of directors on the Effective Date. Dr. Gold will continue to serve the Board of Directors until that time. Joseph "Adrian" Tyndall, MD, MPH, FACEP is a recognized leader in emergency medicine, educational leadership and research and is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine. Previously, Dr. Tyndall spent more than 13 years as Professor, Emergency Medicine Department Chair, Trauma Researcher and Interim Dean and Associate Vice President at the University of Florida College of Medicine and UF Health. A graduate of the University of Maryland School of Medicine including the emergency medicine residency program at the University of Maryland Medical System, Dr. Tyndall received a master's degree in Health Services Management and Health Policy from Columbia University, and a bachelor's degree in Chemistry from The George Washington University. He is board-certified in emergency medicine by the American Board of Emergency Medicine and an American College of Emergency Physicians Fellow. Dr. Tyndall is the current President of the Society for Academic Emergency Medicine Foundation and was also recently elected to serve a two year term on the administrative board of the Council of Deans of the Association of American Medical Colleges (AAMC). He has researched and published on traumatic and ischemic brain injuries, is an editor for a leading emergency medicine reference textbook and is known worldwide in the field of emergency medicine. Tillkännagivande • Oct 21
AxoGen, Inc. to Report Q3, 2022 Results on Nov 08, 2022 AxoGen, Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 08, 2022 Reported Earnings • Aug 04
Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.19 loss in 2Q 2021) Second quarter 2022 results: US$0.18 loss per share (up from US$0.19 loss in 2Q 2021). Revenue: US$34.5m (up 2.6% from 2Q 2021). Net loss: US$7.74m (loss narrowed 2.0% from 2Q 2021). Over the next year, revenue is forecast to grow 17%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 3% per year. Tillkännagivande • Jul 12
Axogen, Inc. Appoints William Burke to Board of Directors Axogen, Inc. announced that, effective July 11, 2022, William Burke has been appointed to its Board of Directors and will serve as chair of the Audit Committee. Mr. Burke is a recognized finance leader in the medical technology industry with more than 25 years of experience in senior leadership positions, including at Haemonetics, Medtronic, and Covidien. Burke was the executive vice president, chief financial officer of Haemonetics Corporation from August 2016 to June 2022 with responsibility for the global finance organization including investor relations. From July 2014 to July 2016, Burke served as chief integration officer and vice president, Integration for Medtronic plc and was a member of its executive committee. In that role, he was responsible for ensuring the successful integration of Medtronic with Covidien plc following its acquisition by Medtronic. Prior to joining Medtronic, Burke spent more than 20 years in finance and business development leadership roles at Covidien, including chief financial officer for Covidien Europe based in Zurich, vice president of Corporate Strategy and Portfolio Management and vice president of Financial Planning and Analysis. He also previously held key positions within Tyco Healthcare, including the financial controller of Valleylab, managing director of the Covidien Group in Switzerland, and international controller. He began his career as an auditor with KPMG. He currently serves on the board of directors of MiroMatrix. He received his Bachelor of Science degree in Business Administration from Bryant College. Reported Earnings • May 06
First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 1Q 2021) First quarter 2022 results: US$0.27 loss per share (down from US$0.16 loss in 1Q 2021). Revenue: US$31.0m (flat on 1Q 2021). Net loss: US$11.5m (loss widened 72% from 1Q 2021). Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 15
AxoGen, Inc., Annual General Meeting, May 25, 2022 AxoGen, Inc., Annual General Meeting, May 25, 2022, at 08:15 Eastern Daylight. Agenda: To consider electing eight members to board of directors to hold office for the ensuing year and until their successors are elected and qualified; to consider ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2022; to consider approving compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement; to consider amendments; and to consider similar matters. Tillkännagivande • Apr 14
AxoGen, Inc. to Report Q1, 2022 Results on May 04, 2022 AxoGen, Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022 Tillkännagivande • Apr 03
AxoGen, Inc. Announces Board Changes On March 29, 2022, Quentin S. Blackford notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Audit Committee and Compensation Committee, effective as of 11:59 PM EST on March 30, 2022. Mr. Blackford’s decision to resign was not associated with or attributable to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices, or otherwise. To fill the vacancies on the Board committees created by Mr. Blackford’s departure, the Board has, in each case, effective as of March 30, 2022 (i) appointed John H. Johnson to serve on the Audit Committee as its chair, and (ii) appointed Alan M. Levine to serve on the Compensation Committee. Reported Earnings • Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.66 loss per share (down from US$0.59 loss in FY 2020). Revenue: US$127.4m (up 13% from FY 2020). Net loss: US$27.0m (loss widened 13% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. 
